The 177Lu-PSMA-617 treatment allows for more patients to benefit from the treatment. It enables doctors to determine how well a treatment is actually working. Patients have superior disease ...

GIZ943, also known as [177Lu] Lu-EVS459, is a radioligand therapy that targets cells that express folate receptor alpha (FRα). The spokesperson said Novartis stopped development “based on an ...

Patients with detectable ctDNA before treatment had a shorter duration of clinical benefit and shorter overall survival. Having detectable circulating tumor DNA (ctDNA) before treatment is ...

Prostate cancer. Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177lu-labeled ...

Dr. Abdul Baseet Arham presented an analysis of the efficacy and safety of 225Ac-J591 PSMA-targeted radionuclide therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with prior ...

6 Safety was consistent with the approved product label. 5. 177Lu-PSMA-617 for PSMA+ Metastatic Castration-Resistant Prostate Cancer (mCRPC) On March 28, the FDA expanded the label of lutetium Lu 177 ...

177Lu-PSMA-617 is now approved for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. The phase 3 PSMAfore trial showed a 59% reduction in radiographic progression or ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 ...

ProstACT GLOBAL assesses 177Lu-TLX591 plus standard care in metastatic castration-resistant prostate cancer. The study uses PSMA-targeted radionuclide with lutetium 177, focusing on external ...

Suggested remit: To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that ...